MX2022006728A - Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. - Google Patents
Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.Info
- Publication number
- MX2022006728A MX2022006728A MX2022006728A MX2022006728A MX2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- methods
- cancer
- treatment
- immune checkpoint
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006728A true MX2022006728A (es) | 2022-06-09 |
Family
ID=75977756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006728A MX2022006728A (es) | 2020-05-12 | 2021-05-12 | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20220363762A1 (enExample) |
| EP (1) | EP4021940A1 (enExample) |
| JP (2) | JP7387912B2 (enExample) |
| KR (1) | KR20230009354A (enExample) |
| CN (1) | CN114729054A (enExample) |
| AU (3) | AU2021269832B2 (enExample) |
| BR (1) | BR112022021893A2 (enExample) |
| CA (1) | CA3158607A1 (enExample) |
| IL (2) | IL311936A (enExample) |
| MX (1) | MX2022006728A (enExample) |
| TW (2) | TW202535468A (enExample) |
| WO (1) | WO2021228978A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024054897A1 (en) * | 2022-09-07 | 2024-03-14 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| AU2003221888B2 (en) | 2002-04-11 | 2008-11-06 | Medimmune, Llc | Preservation of bioactive materials by spray drying |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| KR20100107083A (ko) | 2002-12-17 | 2010-10-04 | 메디뮨 엘엘씨 | 생물활성 물질의 고압 분무 건조 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| HK1247578A1 (zh) * | 2015-04-01 | 2018-09-28 | Medimmune Limited | 用於治疗非小细胞肺癌的组合抗pd-l1和抗ctla4抗体 |
| US11214620B2 (en) * | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| CN109863402A (zh) * | 2016-09-27 | 2019-06-07 | 鼎航医药股份有限公司 | 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定 |
| WO2018187227A1 (en) * | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
| KR102693361B1 (ko) * | 2017-05-26 | 2024-08-09 | 브루인 바이오사이언시스, 인크. | 화학색전제 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2019241742A1 (en) * | 2018-06-14 | 2019-12-19 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
-
2021
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 IL IL297640A patent/IL297640A/en unknown
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt unknown
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024016209A (ja) | 2024-02-06 |
| CA3158607A1 (en) | 2021-11-18 |
| AU2024202963A1 (en) | 2024-05-30 |
| BR112022021893A2 (pt) | 2022-12-20 |
| KR20230009354A (ko) | 2023-01-17 |
| EP4021940A1 (en) | 2022-07-06 |
| US20210355224A1 (en) | 2021-11-18 |
| AU2024266949A1 (en) | 2024-12-19 |
| CN114729054A (zh) | 2022-07-08 |
| AU2024202963B2 (en) | 2025-11-20 |
| WO2021228978A1 (en) | 2021-11-18 |
| JP7387912B2 (ja) | 2023-11-28 |
| JP2023524359A (ja) | 2023-06-12 |
| TWI870592B (zh) | 2025-01-21 |
| IL297640A (en) | 2022-12-01 |
| US20220363762A1 (en) | 2022-11-17 |
| TW202535468A (zh) | 2025-09-16 |
| TW202207976A (zh) | 2022-03-01 |
| US20240239893A1 (en) | 2024-07-18 |
| IL311936A (en) | 2024-06-01 |
| AU2021269832B2 (en) | 2024-09-19 |
| AU2021269832A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MY191423A (en) | Binding molecules specific for cd73 and uses thereof | |
| MX2025008444A (es) | Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16 | |
| EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
| ZA201806397B (en) | Humanized anti clever-1 antibodies and their use | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MY208743A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2022006147A (es) | Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. | |
| MX2022006148A (es) | Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit. | |
| MX2023013726A (es) | Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso. | |
| PH12020551453A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2021005686A (es) | Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. | |
| CR20230150A (es) | Combinaciones de lurbinectedina | |
| MX2023013574A (es) | Combinacion farmaceutica que comprende un anticuerpo anti-cd205 y un inhibidor del punto de control. |